SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (418)1/15/1999 1:48:00 PM
From: BRAVEHEART  Respond to of 1073
 
Hi Gang,

Scratch ARNX. It appears to have been way overvalued historically ( charts ). The product market size for the NDA is a only few thousand. It's potential other indications suggest a market size of 1 million. But we are talking many indications ( smaller markets ) and many clinicals later. For the P-3 product it is 300,000 globally. Early results were encouraging but I wouldn't expect too much. Besides the stock is currently under dilution from a offering.

BEST WISHES
LONE WOLF



To: BRAVEHEART who wrote (418)2/4/1999 4:55:00 PM
From: BRAVEHEART  Respond to of 1073
 
Looks like Atragen recieved a warm response to the FDA consideration. I don't get it. Maybe I am missing something. To me the market potential looks rather small. Is anyone familiar with Atragen?

Aronex Pharmaceuticals Receives Acceptance of NDA for Atragen(R)

biz.yahoo.com

LONE WOLF


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News